Results 161 to 170 of about 1,055,467 (319)

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

open access: yesMolecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni   +11 more
wiley   +1 more source

Therapeutics Letter 41

open access: yes, 2001
Therapeutics Letter 41 considers treatment of asymptomatic bacteriuria in pregnancy using Cochrane systematic review evidence. Reliable sources of best available evidence are an aid to practice.
Therapeutics Initiative (University of British Columbia)
core  

Deciphering transcriptional plasticity in pancreatic ductal adenocarcinoma reveals alterations in sensory neuron innervation

open access: yesMolecular Oncology, EarlyView.
Pancreatic sensory neurons innervating healthy and PDAC tissue were retrogradely labeled and profiled by single‐cell RNA sequencing. Tumor‐associated innervation showed a dominant neurofilament‐positive subtype, altered mitochondrial gene signatures, and reduced non‐peptidergic neurons.
Elena Genova   +14 more
wiley   +1 more source

ErbB Receptor Feedback Inhibitor 1 Mutation in Biliary Tract Cancers: Turning Resistance Into Response. [PDF]

open access: yesJCO Precis Oncol
Peshin S   +10 more
europepmc   +1 more source

Therapeutics Letter 14

open access: yes, 1996
Therapeutics Letter 14 discusses menopausal hormone therapy. Education, support and non-drug therapies are essential for all menopausal women. Short-term hormone therapy has a useful role in selected women with established symptoms or disease.
Therapeutics Initiative (University of British Columbia)
core  

Differential expression of cancer‐related genes supports prediction of poor response to first‐line treatments in T‐ALL pediatric patients with high minimal residual disease

open access: yesMolecular Oncology, EarlyView.
In the present work, we have identified a transcriptional signature based on the differential expression of six genes (BCL2&MAST4, HSH2D&LAT2, METRN&PITPNM2) that would facilitate the early detection of T‐cell acute lymphoblastic leukemia (T‐ALL) patients prone to a poor treatment response and could be implemented at diagnosis, along with other risk ...
Antonio Lahera   +11 more
wiley   +1 more source

EV-103 dose escalation/cohort A: 5-year follow-up of enfortumab vedotin plus pembrolizumab in previously untreated locally advanced/metastatic urothelial carcinoma. [PDF]

open access: yesESMO Open
Rosenberg JE   +19 more
europepmc   +1 more source

CCDC80 suppresses high‐grade serous ovarian cancer migration via negative regulation of B7‐H3

open access: yesMolecular Oncology, EarlyView.
PAX8 is a lineage‐specific master regulator of transcription in high‐grade serous ovarian cancer (HGSC) progression. We show for the first time that PAX8 facilitates proliferation and metastasis by repressing the cell autonomous tumor suppressor CCDC80 and inducing B7‐H3 expression.
Aya Saleh   +12 more
wiley   +1 more source

Therapeutics Letter 50

open access: yes, 2003
Therapeutics Letter 50 examines evidences for blood pressure lowering from the DASH trials. Substantial BP lowering can be achieved by a reduced dietary sodium intake, the DASH diet, or a combination of the two.
Therapeutics Initiative (University of British Columbia)
core  

Home - About - Disclaimer - Privacy